[A controlled study of chemiluminescent enzyme immunoassay for the measurement of estrogen receptor in tissue of gynecological neoplasms].
In this study, chemiluminescent enzyme immunoassay (CLEIA) has been developed for the measurement of estrogen receptor (ER) in 34 gynecological oncological tissues from 15 cases of endometrial carcinoma, 15 cases of ovarian tumors and 4 cases of other gynecological tumors. The accuracy, specificity and sensitivity of CLEIA for ER were compared with that of dextran-coated charcoal (DCC) and enzyme immunoassay (EIA).


RESULTS
(1) the standard curve of ER-CLEIA showed a significant linear correlation between the luminosity and ER concentration (r = 0.9786, P < 0.001); (2) The results of CLEIA and that of the other two methods were compared; the correlation coefficients were > 0.8 and their corresponding rates were > 90%; (3) the positive rate of ER determined by these three methods showed no significant differences, however, the mean value of ER-CLEIA was the highest among them. It is concluded that the CLEIA has a higher sensitivity than that of the other two methods for the measurement of ER.
Tongji Hospital of Tongji Medical University, Wuhan.
M J
MJ
Gu
Y K
YK
Zhou
W
W
Zheng
D000230:Adenocarcinoma / Q000737:chemistry; D018282:Cystadenocarcinoma, Mucinous / Q000737:chemistry; D018293:Cystadenoma, Serous / Q000737:chemistry; D016889:Endometrial Neoplasms / Q000737:chemistry*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008163:Luminescent Measurements; D010051:Ovarian Neoplasms / Q000737:chemistry*; D011960:Receptors, Estrogen / Q000032:analysis*; D012680:Sensitivity and Specificity
D011960:Receptors, Estrogen